You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension
SBC: INOVODEL, INC. Topic: NHLBISUMMARY Patients with pulmonary hypertension (PH) experience low oxygen saturation, shortness of breath, low quality of life, and a short life span (lt10 years) following diagnosis. These patients frequently present to emergency rooms, and many are admitted to intensive care units (ICUs), straining the health care system. Despite therapy with phosphodiesterase-5 inhibitors, prostacyclin analogs, a ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises and Experts
SBC: Insitehub LLC Topic: NIGMSSummary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer i ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention
SBC: FORTISCIENCE, INC. Topic: NHLBIProject Summary Project Title: Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention. Atherosclerosis affects more than 18 million Americans and is a major cause of cardiovascular diseases and acute cardiovascular events, such as heart attack and stroke. Current interventions include changes to diet and exercise, smoking cessation, and treatment with st ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of multimode vacuum ionization for use in medical diagnostics
SBC: MSTM LLC Topic: NIAIDThere is a critical need for rapid and cost-effective means for the detection of e.g. infectious diseases at an early stage, drug overdoses, and other health related testing necessities. Thus, significant commercial opportunities exist because of the lack of these capabilities as painfully “demonstrated” in the current pandemic. Mass spectrometry (MS), because of its ability to detect hundreds ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Amino Acids and Pediatric Hepatic Steatosis
SBC: THE AMINO COMPANY LLC Topic: 3007. Project Summary/Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in North America (1). Hepatic steatosis (HS) is the hallmark of NAFLD (2). NAFLD may transition in sub-groups to chronic inflammation (non- alcoholic steatohepatitis, NASH), and ultimately to cirrhosis. HS is prevalent in all stages of NAFLD. 3-10% of all children in the US and 40-70% of obese ch ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease
SBC: EINSENCA INC. Topic: NIAAlzheimer's disease (AD) is a devastating and progressive disease without a cure. Neuroinflammation is now recognized as a key early event in the development of AD. Aberrant neuroinflammatory response activates immune cells that can increase oxidative stress, and oxidative stress can directly damage neurons and axons, cause demyelination, and break down the blood-brain barrier (BBB). Thus, damagin ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment
SBC: En Solucion Inc Topic: FDARecent foodborne illness outbreaks traced to contaminated field harvesting equipment have highlighted the need for incorporating improved sanitization practices at the time of harvest. Field- harvested specialty crops represent 50% of the top ten foods linked to major recalls and outbreaks over the past five years. Proper sanitization of outdoor harvest equipment is made complicated by operational ...
SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration -
ARPA-H PHASE II SBIR AWARD, TOPIC 03- ROBOTICS FOR AUTONOMOUS SOFT TISSUE SURGERY TITLE: ADVANCED IMAGING AIDED AUTONOMOUS ROBOTIC CHOLECYSTECTOMY
SBC: OPTOSURGICAL LLC Topic: AH03This ARPA-H SBIR Phase II project aims to develop an 'autonomous' minimally invasive surgery approach, enhancing outcomes in procedures like laparoscopic cholecystectomy through advanced robotic tools and a 'smart' vision framework. The research team will explore whether the novel robotic platform can elevate the safety and efficiency of gallbladder removal surgery by integrating supervised autono ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
ARPA-H SBIR PHASE II TOPIC 4 FOR INTRA-OPERATIVE CONTRAST AGENTS
SBC: OPTOSURGICAL LLC Topic: AH04The project aims to advance the development of BL-760, a near-infrared contrast agent designed for clear intraoperative identification of bile ducts. This novel dye addresses the significant medical issue of bile duct injury during hepatobiliary surgeries (e.g., cholecystectomy, hepatectomy), impacting over 1 million patients annually. The project plans to produce BL-760 with high quality standard ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive PSA Quantitation Using Smartphone to Reduce Prostate Cancer Monitoring Disparities
SBC: Instanosis, Inc. Topic: 102Project SummaryProstate cancer is a leading cause of cancer mortality in medically underserved men, due to limited access to quality health care resources. Longitudinal monitoring of very low blood prostate specific antigen (PSA) concentrations (tens of pg/mL) is an important tool for clinical surveillance of patients post radical prostatectomy or radical radiotherapy. Such monitoring requires hig ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health